Cited 0 times in
CYP2C19 Polymorphisms and Smoking Status Affects Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 남효석 | - |
dc.contributor.author | 이경열 | - |
dc.contributor.author | 한상원 | - |
dc.date.accessioned | 2020-02-11T06:07:10Z | - |
dc.date.available | 2020-02-11T06:07:10Z | - |
dc.date.issued | 2019 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/174542 | - |
dc.description.abstract | Background: The “comparison of triflusal and clopidogrel effects in secondary prevention of stroke based on cytochrome P450 2C19 (CYP2C19) genotyping (MAESTRO)” study was a prospective, multicenter, randomized, open-label, and blind genotype trial. We performed a subgroup analysis of the MAESTRO study to explore the relationship between VerifyNow P2Y12 assay with regard to CYP2C19 polymorphisms and smoking status in patients with non-cardiogenic ischemic stroke who underwent clopidogrel treatment. Methods: For the study, patients treated with clopidogrel and who underwent VerifyNow P2Y12 assay was selected from the MAESTRO study. Results: Of the 393 patients in 18 hospitals, 256 (65%) patients in 12 hospitals were entered for this subgroup analysis. P2Y12 reaction unit (PRU) was significantly lower and percent inhibition (% INH) was higher in the current smoking group than in the nonsmoking group (p<0.001). The same results were also observed in the good genotype group when compared with the poor genotype group (p<0.001). Among the groups, significant lower PRU and higher % INH was demonstrated in current smoking with good genotype group. However, there was no difference in PRU and % INH between current smoking with poor genotype group and nonsmoking with good genotype group, suggesting that clopidogrel activity was concurrently related to CYP2C19 polymorphisms and smoking status. Conclusions: Regarding secondary stroke prevention, patients who were current smokers and had a poor genotype for clopidogrel metabolism may benefit from clopidogrel treatment similar to that in patients who were nonsmokers and had a good genotype. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Society of Cardiovascular Disease Prevention | - |
dc.relation.isPartOf | Cardiovascular Prevention and Pharmacotherapy | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | CYP2C19 Polymorphisms and Smoking Status Affects Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurology (신경과학교실) | - |
dc.contributor.googleauthor | Sang Won Han | - |
dc.contributor.googleauthor | Yong-Jae Kim | - |
dc.contributor.googleauthor | Woo-Keun Seo | - |
dc.contributor.googleauthor | Sungwook Yu | - |
dc.contributor.googleauthor | Hyo Suk Nam | - |
dc.contributor.googleauthor | Sung Sang Yoon | - |
dc.contributor.googleauthor | Seo Hyun Kim | - |
dc.contributor.googleauthor | Jong Yun Lee | - |
dc.contributor.googleauthor | Jun Hong Lee | - |
dc.contributor.googleauthor | Yang-Ha Hwang | - |
dc.contributor.googleauthor | Jun Lee | - |
dc.contributor.googleauthor | Kyung-A Lee | - |
dc.contributor.googleauthor | Kyung-Yul Lee | - |
dc.identifier.doi | 10.36011/cpp.2019.1.e8 | - |
dc.contributor.localId | A01273 | - |
dc.contributor.localId | A02648 | - |
dc.contributor.localId | A04285 | - |
dc.relation.journalcode | J03760 | - |
dc.identifier.eissn | 2671-700X | - |
dc.subject.keyword | Clopidogrel | - |
dc.subject.keyword | Polymorphism, genetic | - |
dc.subject.keyword | Polymorphism, Single nucleotide | - |
dc.subject.keyword | Smoking | - |
dc.subject.keyword | Stroke | - |
dc.contributor.alternativeName | Nam, Hyo Suk | - |
dc.contributor.affiliatedAuthor | 남효석 | - |
dc.contributor.affiliatedAuthor | 이경열 | - |
dc.contributor.affiliatedAuthor | 한상원 | - |
dc.citation.volume | 1 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 63 | - |
dc.citation.endPage | 70 | - |
dc.identifier.bibliographicCitation | Cardiovascular Prevention and Pharmacotherapy, Vol.1(2) : 63-70, 2019 | - |
dc.identifier.rimsid | 64610 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.